Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine

Virology Journal

Volumn 8, Issue , 2011, Pages

  Zhang, Xiancheng ^a   He, Peng ^a   Hu, Zhongyu ^a   Wang, Xingtai ^b   Liang, Zhenglun ^a  

^a NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^b MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; B7 ANTIGEN; BW 006; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; RECOMBINANT HEPATITIS B SURFACE ANTIGEN; UNCLASSIFIED DRUG; CD86 PROTEIN, MOUSE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; CYTOKINE; HEPATITIS B ANTIBODY; OLIGODEOXYRIBONUCLEOTIDE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS B; IMMUNE RESPONSE; MOUSE; NONHUMAN; SPLEEN CELL; TH1 CELL; ANIMAL; BLOOD; CHEMISTRY; IMMUNOLOGY; SECRETION;

MUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; CYTOKINES; DENDRITIC CELLS; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; RECOMBINANT PROTEINS;

EID: 79951853968     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-78     Document Type: Article

References (28)

1. Immunology of hepatitis B virus and hepatitis C virus infection. B Rehermann M Nascimbeni, Nat Rev Immunnol 2005 5 3 215 229 10.1038/nri1573 (Pubitemid 40364823)
2. Viral hepatitis B: aspects of environmental control. WW Bond NJ Petersen MS Favero, Health Lab Sci 1977 14 4 235 252 914523 (Pubitemid 8324740)
3. The emergence of hepatitis B as a sexually transmitted disease. MJ Alter HS Margolis, Med Clin North Am 1990 74 6 1529 1541 2246951 (Pubitemid 20384860)
4. Programmes and projects - Immunization service delivery and accelerated disease control - New vaccines and technologies - Hepatitis B. World Health Organization, 2008 http://www.who.int/immunization-delivery/new-vaccines/hepb/ en/index.html
5. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. XF Liang S Bi W Yang L Wang G Cui Y Zhang Y Liu X Gong Y Chen Y Wang H Zheng F Wang J Guo Z Jia J Ma H Wang H Luo L Li S Jin SC Hadler Y Wang, Vaccine 2009 27 47 6550 6557 10.1016/j.vaccine.2009. 08.048 19729084
6. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. SL Hem H Hogenesch, Expert Rev Vaccines 2007 6 5 685 698 10.1586/14760584.6.5.685 17931150 (Pubitemid 47607846)
7. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. GL Morefield A Sokolovska D Jiang H HogenEsch JP Robinson SL Hem, Vaccine 2005 23 13 1588 1595 10.1016/j.vaccine.2004.07.050 15694511 (Pubitemid 40203396)
8. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. M Kool T Soullié M van Nimwegen MA Willart F Muskens S Jung HC Hoogsteden H Hammad BN Lambrecht, J Exp Med 2008 205 4 869 882 10.1084/jem.20071087 18362170 (Pubitemid 351549884)
9. Hepatitis B virus infection. WM Lee, N Engl J Med 1997 337 24 1733 1745 10.1056/NEJM199712113372406 9392700 (Pubitemid 27527771)
10. CpG motifs in bacterial DNA trigger direct B-cell activation. AM Krieg AK Yi S Matson TJ Waldschmidt GA Bishop RG Teasdale GA Koretzky DM Klinman, Nature 1995 374 6522 546 549 10.1038/374546a0 7700380
11. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. JM Mauri M Vallès, Collaborative Group of Girona. Nephrol Dial Transplant 1997 12 4 729 732 10.1093/ndt/12.4.729 (Pubitemid 27170428)
12. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. AE Singh SS Plitt C Osiowy K Surynicz E Kouadjo J Preiksaitis B Lee, J Viral Hepat 2010 20546502
13. Failure to respond to hepatitis B vaccine in children with celiac disease. SD Park J Markowitz M Pettei T Weinstein CP Sison SR Swiss J Levine, J Pediatr Gastroenterol Nutr 2007 44 4 431 435 10.1097/MPG.0b013e3180320654 17414139 (Pubitemid 46573225)
14. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. MO Oyewumi A Kumar Z Cui, Expert Rev Vaccines 2010 9 9 1095 1107 10.1586/erv.10.89 20822351
15. HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen. R Saenz CD Souza CT Huang M Larsson S Esener D Messmer, Vaccine 2011 28 47 7556 7562 10.1016/j.vaccine.2010.08.054
16. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent. N Pakravan SM Hashemi ZM Hassan, Cell Stress Chaperones 2011 16 1 41 48 10.1007/s12192-010-0219-5 20730610
17. Mode of action of adjuvants: implications for vaccine safety and design. B Mastelic S Ahmed WM Egan G Del Giudice H Golding I Gust P Neels SG Reed RL Sheets CA Siegrist PH Lambert, Biologicals 2010 38 5 594 601 10.1016/j.biologicals.2010.06.002 20659806
18. Adjuvants - essential components of new generation vaccines. K Dzierzbicka AM Koodziejczyk, Postepy Biochem 2006 52 2 204 211 17078510
19. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. R Schirmbeck K Melber A Kuhröber ZA Janowicz J Reimann, J Immunol 1994 1529 3 1110 1119 (Pubitemid 24134336)
20. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. HL Davis R Weeratna TJ Waldschmidt L Tygrett J Schorr AM Krieg, J Immunol 1998 160 2 870 876 9551923 (Pubitemid 28049329)
21. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. S Rossol G Marinos P Carucci M V Singer R Williams NV Naoumov, J Clin Invest 1997 99 12 3025 3033 10.1172/JCI119498 9185527 (Pubitemid 27278680)
22. Complexities of Cd28/B7: ctla-4 co-stimulatory pathways in autoimmunity and transplantation. B Salomon JA Bluestone, Annu Rev Immunol 2001 19 225 10.1146/annurev.immunol.19.1.225 11244036
23. The expanding world of co-stimulation: the two-signal model revisited. CA Chambers, Trends Immunol 2001 22 4 217 223 10.1016/S1471-4906(01)01868-3 11274928 (Pubitemid 32673662)
24. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response. E Alvarez E Moqa J Barquinero J Sierra J Briones, Gene Ther 2010 17 4 469 477 10.1038/gt.2009.150 20010627
25. Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy. K Holmstrøm AW Pedersen MH Claesson MB Zocca SS Jensen, Hum Immunol 2010 71 1 67 73 19819280
26. Expression of maturation markers on murine dendritic cells in response to group A streptococcal lipopeptide vaccines. M Yong D Mitchell A Caudron I Toth C Olive, Vaccine 2009 27 25-26 3313 3318 10.1016/j.vaccine.2009.01.087 19200839
27. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. S Kakumu S Ito T Ishikawa Y Mita T Tagaya Y Fukuzawa K Yoshioka, J Gastroenterol Hepatol 2000 15 4 431 436 10.1046/j.1440-1746.2000.02161.x 10824889 (Pubitemid 30262212)
28. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. ML Op den Brouw RS Binda MH van Roosmalen U Protzer HL Janssen RG van der Molen AM Woltman, Immunology 2009 126 2 280 289 10.1111/j.1365-2567.2008.02896.x 18624732